Teleflex (TFX) investor relations material

Strategic business separation and transaction process

• Announced a business separation with options for a spin-off or sale, aiming to maximize shareholder value, with a targeted completion in mid-2026 for either path.

• Significant inbound interest from both financial sponsors and strategics, with most interest focused on acquiring the entirety of NewCo.

• Management teams for both entities have been identified, and data rooms and presentations for interested parties are underway.

• Proceeds from a potential sale would be used to pay down debt and return capital to shareholders.

Integration and performance of acquired vascular business

• Integration of the Biotronic Vascular business is progressing well, with strong collaboration and no surprises ten weeks in.

• The business is expected to generate over $200 million in the second half of the year, with mapped cross-training and positive team morale.

• Product and geographic synergies are being realized, including expanded access to cath labs and new sales channels.

• Cross-training and territory realignment are underway to maximize sales efficiency and deepen customer relationships.

Innovation and product pipeline highlights

• FreeSolve, a bioabsorbable magnesium scaffold, is in clinical trials in Europe and will begin US trials in 2026, aligning with the trend of 'leave nothing behind' in cardiology.

• Baragel, a prostate cancer radiation spacing technology, continues strong growth, recently gained approval in Japan, and is expanding indications to post-prostatectomy cases.

• UroLift in the BPH market is poised for recovery if proposed reimbursement changes are finalized, potentially doubling profitability in office settings.